Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline results expected this month Completed randomized portion of fasedienol Phase 2 repeat dose study; topline results expected in third quarter 2026 Achieved minimum ICH E1

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 9, 2026-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 27, 2026-- Vistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the

Dr. Angelov brings extensive industry experience across multiple therapeutic areas SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 19, 2026-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 14, 2026-- Vistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President

Fasedienol nasal spray has been well-tolerated in patients with social anxiety disorder with no new drug-related safety findings after as-needed use in daily life for up to 12 months Clinically relevant improvement in social anxiety over time was observed on both clinician-administered and

Topline results for the randomized portion of PALISADE-4 are expected in the second quarter of 2026 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 8, 2026-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 22, 2026-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 3, 2026-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 25, 2026-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, will present